Skip to main navigation

Skip to Content

News
Contact Us
Investors
- Overview
- Events and Presentations
- SEC Filings
- Stock Information
- Corporate Governance
- Investor FAQs
- Email Alerts

Home
About
- About Cullinan
- Leadership
- Partnerships
Research
- R&D
- Programs
- Pipeline
For Patients
- Patient Programs
- Clinical Trials
Working at Cullinan
- Our People
- Careers

News Releases

Year

Cullinan Oncology to Participate in Upcoming Investor Conferences

September 6, 2023

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 10, 2023

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

August 9, 2023

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

August 3, 2023

Cullinan Oncology to Participate in Upcoming Investor Conferences

July 31, 2023

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

May 25, 2023

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

April 26, 2023

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

April 20, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

March 27, 2023

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Connect with Us

Follow Us

Site - Social

Site - Footer

Connect With Us
About Us
Terms of Use/Privacy
Accessibility Policy

© COPYRIGHT 2023 Cullinan Oncology, Inc. | ALL RIGHTS RESERVED